Mena Nutraceuticals Market Size to Exceed USD 27.9 Bn by 2032

The Mena Nutraceuticals Market, estimated at USD 17.15 Bn in 2025, is expected to exhibit a CAGR of 7.2% and reach USD 27.9 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The key market players are focused on adopting growth strategies such as product launches, and this is expected to drive the MENA nutraceuticals market growth during the forecast period. For instance, in March 2020, Dubai Energy Drink, a Food and Beverage Services announced the launch of a product energy drink as a functional beverage made in Dubai, and plans to expand across the UAE and go global. The company has been allowed to cater to health trends by allowing for a low-calorie version made from stevia. It is a plant-based sweetener with zero additional calories. However, each serving will have around three calories. Lastly, the company stated that it can manufacture around 1 million cans in a day to cater to the rising demand from the young Emirati students.

MENA Nutraceuticals Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.

COVID-19 had  positive impact on the MENA Nutraceuticals Market, due to the increase in demand of nutraceuticals to fight with the chronic disease which help boost the immunity during the pandemic and post-pandemic. Nutraceuticals have emerged as potential compounds to attenuate the COVID-19 complications. Precisely, these food additives strengthen the overall COVID treatment, and enhance the immunity of a person. For instance, in October 2022, according to an article published by the Journal of Food Biochemistry, nutraceuticals such as probiotics, vitamins, polyunsaturated fatty acids, trace minerals, and medicinal plants are used as potential alternatives to current therapeutic options for the effective management of various diseases including COVID-19.

MENA Nutraceuticals Market: Key Developments

In January 2021, Agthia Group, a UAE-based food and beverages company, announced that the strategic acquisition of a majority stake in Nabil Foods, one of the regional producers of frozen and chilled processed protein products distributed in more than 20 local and international markets.

In December 2020, BioHarvest Sciences Inc., the developer and exclusive owner of the proprietary and patent-protected BioFarming technology, reported that the VINIA nutraceutical e-commerce launch in Israel's first full month of November had sales orders that were more than expected, totaling US$ 101,000.

In March 2021, BioHarvest Sciences Inc., the developer and exclusive owner of the proprietary and patent-protected BioFarming technology, received approval from the Ministry of Health in Israel to include VINIA, its proprietary red grape cell product, in a health snack bar.

Browse 34 Market Data Tables and 26 Figures spread through 220 Pages and in-depth TOC on “MENA Nutraceuticals Market”- Forecast to 2030, MENA Nutraceuticals Market, By Product type (Calcium Supplement Tablets and Gummies, Probiotics Supplement Tablets & Capsules, Collagen Peptide Powder Jar or Sachet, Iron in Tablet and Gummies & Syrup, Folic Acid Tablet, Pyridoxine Tablet, Rocket Seed Oil in Soft Gel, Prenatal Vitamin in Tablet and Gummies, Chaste Berry in Powder and Tablet and Capsule, Natural Eggshell Membrane in Capsule, Melatonin in Tablet, Vitamin C in Tablet, Inositol in Tablet, Whey Protein in Powder and Sachet, Biotin in Tablet, Hypericum perforatum Extract in Capsule, Vitamin D3 in Soft Gel Capsule and Gummies, Omega 3 in Soft Gel and Gummies, Omega 3 Plus Multivitamin in Soft Gel, Gummies Natural Eggshell Membrane in Capsule, CBD (CBD Tinctures, Capsules & Soft gels, CBD Gummies, Others), and Others), By Application (Cancer, Diabetes, Heart Disorders, Hypertension, Obesity, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Convenience Store, Hypermarket/ Supermarket and Online Pharmacies), and By Region (Middle East and North Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/mena-nutraceuticals-market-3795

Key Takeaways of the MENA Nutraceuticals Market:

• The MENA nutraceuticals market is expected to exhibit a CAGR of 7.2% during the forecast period. The collaboration with emerging economies offers lucrative growth opportunities for players in the MENA nutraceuticals market. For instance, in December 2020, Rousselot, manufacturer of gelatin and collagen peptides and a supplier to the food, pharmaceutical, nutritional, and technical industries, announced the launch of new gelatin based solution for soft gummies, for children as their potential as a delivery form for nutraceutical and active pharmaceutical ingredients.
• Among application, the diabetes segment is expected to growth in the MENA nutraceuticals market over the forecast period. For instance, in November 2020, according to an article published by the Journal of Clinical Medicine, the age-adjusted prevalence of adult diabetes in the Middle East and North Africa (MENA) region that includes Kuwait, was 12.2%, the highest estimated prevalence of all the IDF (International Diabetes Federation) regions. Prevalence in the MENA region is expected to increase to 13.9% by 2045.
• Among Product Type, the Vitamin D3 in soft gel capsule and gummies segment is expected to hold a dominant position in the MENA nutraceuticals market during the forecast period due to the decrease in the hypovitaminosis D (Vitamin D deficiency). For instance, in February 2022, according to an article published by Journal of PLoS One, in 2020, about 30%–50% of children and adults in the United Arab Emirates (UAE), Australia, Turkey, India, and Lebanon have 25-hydroxyvitamin D levels <20 ng/ml.
• Among Region, the Middle East is expected to dominate the market over the forecast period due to increasing prevalence of chronic diseases. For instance, in October 2022, according to an article published by European Journal of Public Health, the prevalence of self-reported chronic diseases was 23.0%. Obesity, Diabetes and Asthma/Allergies in UAE were the commonest (12.5%, 4.2% & 3.2%, respectively). 34.8% of the students were either overweight or obese. Overall chronic disease prevalence was similar between males and females [27.5% vs 21.8%] though it was significantly higher among postgraduates, students who are older, married and have family history of diabetes. 4.7% of the students reported 2 or more chronic diseases.
• Major players operating in the MENA nutraceuticals market include Nestlé, Nutricia, Unilever, Bionova, BASF SE, Abbott, Arkopharma Laboratories, GSK plc., ADM (Archer Daniels Midland Company), DuPont, Kellogg's Company, Arla Foods amba, DSM, Quantum Naturals Ltd., Adcock Ingram, Ascendis Health Limited, iNova Pharmaceuticals, Vital Health Foods, Jamjoom Pharma, Creso Pharma, and ConnOils LLC.